Back Hepatitis B

Hepatitis B

Chronic Hepatitis B Treatment Guidelines

CHB Treatment Guideline Navigator

Mark Sulkowski from Johns Hopkins and Tram Tran from Cedars Sinai Medical Center help readers understand and make decisions using current guidelines for treatment of people with chronic hepatitis B. This continuing medical education (CME) activity is available for free to all, with credit available for physicians and nurses.

alt

Read more:

Monitoring Inactive Hepatitis B Is Cost-effective but Must Increase to Improve Survival

Lifelong monitoring of people with inactive hepatitis B virus (HBV) infection may be cost-effective, according to a study in China published the December 19 advance online edition of Hepatology. Monitoring and treatment would have to be substantially expanded, however, to achieve significant reductions in liver cancer and hepatitis B-related mortality.

alt

Read more:

AASLD 2013: Tenofovir for Hepatitis B Remains Safe and Effective Over 7 Years

Chronic hepatitis B patients treated with tenofovir (Viread) for 7 years continued to main viral suppression and liver enzyme normalization, while serological response rates continued to increase, according to a poster presented at the 64th AASLD Liver Meeting last month in Washington, DC. Long-term kidney and bone-related side effects remained uncommon.

alt

Read more:

CDC Updates Guidance for Hepatitis B Vaccination of Health-care Providers

The U.S. Centers for Disease Control and Prevention (CDC) has published updated guidance for evaluating and ensuring protection against hepatitis B virus (HBV) for health-care workers, as well as post-exposure prophylaxis recommendations for those without adequate vaccine protection.

alt

Read more:

AASLD 2013: Viral Hepatitis Epidemics in the U.S. and California

Deputy Assistant Secretary for Health Ronald Valdisseri described the hepatitis B and C epidemics in the U.S., the HCV cascade of care, and efforts to combat viral hepatitis at the AASLD Liver Meeting this month in Washington, DC. Public health officials in California also recently released a report on the hepatitis B and C epidemics in that state.

alt

Read more:

Adding Pegylated Interferon to Antivirals for Hepatitis B May Lead to HBsAg Loss

Addition of pegylated interferon to nucleoside/nucleotide antivirals increases the likelihood of hepatitis B surface antigen (HBsAg) loss -- considered a cure -- in people with hepatitis B "e" antigen (HBeAg) negative chronic hepatitis B, according to a report in December 2013 edition of Journal of Clinical Virology.

alt

Read more:

AASLD 2013: Tenofovir Alafenamide Shows Similar Anti-HBV Activity with Less Kidney Toxicity

A new formulation of tenofovir that can be taken at lower doses demonstrated potent activity against hepatitis B virus (HBV) similar to that of the existing formulation in a 28-day study, but with less effect on kidney function, researchers reported at the 64thAASLD Liver Meeting this month in Washington, DC.

alt

Read more:

Hepatitis B and C Reduce Survival by More than 20 Years

People with chronic hepatitis B or C lived about 2 decades less on average than those who did not have these infections, and chronic viral hepatitis was the 15th leading cause of death in the U.S. in 2010, CDC researchers reported in the January 1, 2014, issue of Clinical Infectious Diseases.

alt

Read more:

AASLD 2013: Hepatitis B Vaccine Protection Lasts at Least 30 Years

Hepatitis B vaccination provides long-term protection through 30 years for a majority of recipients, and more than 90% were protected with either initial immunization or a booster, according to a presentation at the 64th AASLD Liver Meeting last week in Washington, DC.

alt

Read more: